Hana Biosciences, Inc. To Present Talvesta™ (Talotrexin) For Injection Completed Phase I Clinical Trial In Non Small Cell Lung Cancer At The EORTC-NCI-AACR Symposium
09 Nov 2006
CollaborateAACR
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Hana Biosciences (NASDAQ:HNAB), a biopharmaceutical company focused on advancing cancer care, will present additional data from the completed Phase I trial results for Talvesta™ (talotrexin) for Injection in non small cell lung cancer (NSCLC) at the 18th Annual EORTC-NCI-AACR symposium on “Molecular Targets and Cancer Therapeutics,” in Prague, Czech Republic. Abstract #464: “Pharmacokinetics of talotrexin (PT-523), a novel aminopterin analogue, in patients with non-small cell lung cancer” will be presented on Friday, November 10th from 12:00pm – 2:00pm.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.